Table 2

Patient characteristics, abnormal screen group (n = 490)
All subjects (n = 490)
N (%)
Age
< 65 years 261 (53%)
> = 65 years 229 (47%)
Mean 65.1
Median 63.5
Range 42-92
Race/ethnicity
African American 332 (68%)
White 105 (21%)
Other 27 (6%)
Not reported 26 (5%)
Screening eligibility
PSA test (> = 4.0 ng/mL) 414 (84%)
Abnormal PSA velocity 39 (8%)
Digital rectal exam 37 (8%)
Baseline PSA
< 4 ng/mL* 37 (8%)
4 ng/mL - 10 ng/mL 318 (65%)
> 10 ng/mL 98 (20%)
Not collected (Screen = DRE) 37 (8%)
Cancer diagnosis
No cancer or resolved with repeat PSA 244 (50%)
Cancer 170 (35%)
Unresolved 76 (16%)

Abbreviations: PSA, prostate specific antigen; ng/mL, Nanogram per milliliter; DRE, Digital rectal exam.

*Values may not sum to all subjects who enrolled on abnormal PSA velocity due to rounded PSA value.

Nonzee et al.

Nonzee et al. BMC Health Services Research 2012 12:340   doi:10.1186/1472-6963-12-340

Open Data